BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 22772980)

  • 21. Spinal cord high-grade infiltrating gliomas in adults: clinico-pathological and molecular evaluation.
    Alvi MA; Ida CM; Paolini MA; Kerezoudis P; Meyer J; Barr Fritcher EG; Goncalves S; Meyer FB; Bydon M; Raghunathan A
    Mod Pathol; 2019 Sep; 32(9):1236-1243. PubMed ID: 31028365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
    Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
    Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isocitrate Dehydrogenase 1 Expression in Canine Gliomas.
    Fraser AR; Bacci B; le Chevoir MA; Long SN
    J Comp Pathol; 2018 Nov; 165():33-39. PubMed ID: 30502793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.
    Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L
    Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas.
    Sloan EA; Cooney T; Oberheim Bush NA; Buerki R; Taylor J; Clarke JL; Torkildson J; Kline C; Reddy A; Mueller S; Banerjee A; Butowski N; Chang S; Mummaneni PV; Chou D; Tan L; Theodosopoulos P; McDermott M; Berger M; Raffel C; Gupta N; Sun PP; Li Y; Shah V; Cha S; Braunstein S; Raleigh DR; Samuel D; Scharnhorst D; Fata C; Guo H; Moes G; Kim JYH; Koschmann C; Van Ziffle J; Onodera C; Devine P; Grenert JP; Lee JC; Pekmezci M; Phillips JJ; Tihan T; Bollen AW; Perry A; Solomon DA
    Acta Neuropathol; 2019 Nov; 138(5):877-881. PubMed ID: 31515627
    [No Abstract]   [Full Text] [Related]  

  • 27. Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas.
    Wang Y; Zhang T; Li S; Fan X; Ma J; Wang L; Jiang T
    Eur J Neurol; 2015 Feb; 22(2):348-54. PubMed ID: 25318355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies.
    Ikota H; Nobusawa S; Arai H; Kato Y; Ishizawa K; Hirose T; Yokoo H
    Brain Tumor Pathol; 2015 Oct; 32(4):237-44. PubMed ID: 26006098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of IDH1 mutation in the plasma of patients with glioma.
    Boisselier B; Gállego Pérez-Larraya J; Rossetto M; Labussière M; Ciccarino P; Marie Y; Delattre JY; Sanson M
    Neurology; 2012 Oct; 79(16):1693-8. PubMed ID: 23035067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.
    Hersh DS; Peng S; Dancy JG; Galisteo R; Eschbacher JM; Castellani RJ; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    J Neurooncol; 2018 Jun; 138(2):241-250. PubMed ID: 29453678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
    Sanson M; Marie Y; Paris S; Idbaih A; Laffaire J; Ducray F; El Hallani S; Boisselier B; Mokhtari K; Hoang-Xuan K; Delattre JY
    J Clin Oncol; 2009 Sep; 27(25):4150-4. PubMed ID: 19636000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IDH1 mutation is associated with seizures and protoplasmic subtype in patients with low-grade gliomas.
    Liubinas SV; D'Abaco GM; Moffat BM; Gonzales M; Feleppa F; Nowell CJ; Gorelik A; Drummond KJ; O'Brien TJ; Kaye AH; Morokoff AP
    Epilepsia; 2014 Sep; 55(9):1438-43. PubMed ID: 24903073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.
    Wang XW; Boisselier B; Rossetto M; Marie Y; Idbaih A; Mokhtari K; Gousias K; Hoang-Xuan K; Delattre JY; Simon M; Labussière M; Sanson M
    Cancer; 2013 Feb; 119(4):806-13. PubMed ID: 23184331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing.
    Li J; Zhang H; Wang L; Yang C; Lai H; Zhang W; Chen X; Wang J
    Mol Med Rep; 2015 Sep; 12(3):4376-4381. PubMed ID: 26130305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brain T1ρ mapping for grading and IDH1 gene mutation detection of gliomas: a preliminary study.
    Cao M; Ding W; Han X; Suo S; Sun Y; Wang Y; Qu J; Zhang X; Zhou Y
    J Neurooncol; 2019 Jan; 141(1):245-252. PubMed ID: 30414094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IDH1 mutation detection by droplet digital PCR in glioma.
    Wang J; Zhao YY; Li JF; Guo CC; Chen FR; Su HK; Zhao HF; Long YK; Shao JY; To Ss; Chen ZP
    Oncotarget; 2015 Nov; 6(37):39651-60. PubMed ID: 26485760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas.
    Loussouarn D; Le Loupp AG; Frenel JS; Leclair F; Von Deimling A; Aumont M; Martin S; Campone M; Denis MG
    Int J Oncol; 2012 Jun; 40(6):2058-62. PubMed ID: 22447191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.
    Yamashita AS; da Costa Rosa M; Borodovsky A; Festuccia WT; Chan T; Riggins GJ
    Neuro Oncol; 2019 Feb; 21(2):189-200. PubMed ID: 30184215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diffuse glioma - Rare homozygous IDH point mutation, is it an oncogenetic mechanism?
    Singh A; Gurav M; Dhanavade S; Shetty O; Epari S
    Neuropathology; 2017 Dec; 37(6):582-585. PubMed ID: 28782849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of isocitrate dehydrogenase 1 mutation in 97 patients with glioma.
    Zhou YX; Wang JX; Feng M; Sun CM; Sun T; Chen GL; Du ZW
    J Mol Neurosci; 2012 Jul; 47(3):442-7. PubMed ID: 22113362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.